Ensysce Biosciences
La Jolla
About Ensysce Biosciences
Ensysce Biosciences develops oral drug delivery technologies targeting opioid misuse and overdose. Its Trypsin-Activated Abuse Protection (TAAP™) platform activates medications only upon ingestion, minimizing abuse through non-oral routes. The Multi-Pill Abuse Resistance (MPAR®) system adds a safeguard against overdose by inhibiting drug activation when excessive doses are consumed. These platforms are applied to treatments for severe pain and opioid use disorder, including PF614 and PF9001. Ensysce's approach has received recognition from the FDA, with TAAP™ designated as a Fast Track development and MPAR® as a Breakthrough Therapy. The company is also exploring the use of nafamostat, a component of its overdose protection products, for treating infections and pulmonary diseases. Its pipeline includes clinical and preclinical programs focused on enhancing the safety of prescription medications. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $147.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2025)
- Ticker: nasdaq:ENSC
- Website: ensysce.com
- Phone: (858)-263-4196
Industries & Categories
Biotechnology, Health Care, Leisure, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ensysce-biosciences-90963 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.